Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 study.

American journal of hematology - 1 Oct 2021

Sarkozy Clémentine, Michot Jean-Marie, Quivoron Cyril, Camara-Clayette Valérie, Danu Alina, Lazarovici Julien, El-Dakdouki Yolla, Saleh Khalil, Ghez David, Rossignol Julien, Baldini Capucine, Arfi-Rouche Julia, Romano-Martin Patricia, Tselikas Lambros, Varga Andrea, Gazzah Anas, Hollebecque Antoine, Lacroix Ludovic, Bahleda Rastislav, Lecourt Hélène, Vergé Veronique, Rahali Wasilla, Cotteret Sophie, Soria Jean-Charles, Dartigues Peggy, Massard Christophe, Ribrag Vincent

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Management

Share to Lymphoma, Large B-Cell, Diffuse

Share to Molecular Targeted Therapy

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Precision Medicine

Source

Identifiers

PMID: 34165816
DOI: 10.1002/ajh.26280

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 study.PMID 34165816Read ↗

Aggressive B-cell lymphoma: chasing the target.Semantic proximity Read ↗

New targeted therapies for malignant lymphoma based on molecular heterogeneity.Semantic proximity Read ↗

Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature.Semantic proximity Read ↗

How should we sequence and combine novel therapies in CLL?Semantic proximity Read ↗

Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplantSemantic proximity Read ↗

CD31 promotes diffuse large B cell lymphoma metastasis by upregulating OPN and mTORSemantic proximity Read ↗

A patient derived xenograft repository capturing clinical and molecular heterogeneity of large B-cell lymphomaSemantic proximity Read ↗

Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplantSemantic proximity Read ↗

[Recent advances in the understanding and treatment of diffuse large B-cell lymphoma].Semantic proximity Read ↗

[Recent advance in peripheral T-cell lymphoma, not otherwise specified].Semantic proximity Read ↗

Analysis of high-risk factors and prognosis of early relapse in 104 patients with natural killer/T-cell lymphoma: a single-center retrospective studySemantic proximity Read ↗

Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.